PMPRB releases updated draft Guidelines for public consultation
| Patented Medicine Prices Review Board Canada | news releases
The PMPRB is holding public consultations on its proposed new pricing Guidelines
News results
Showing 41 - 50 of 80 results
Oncology treatments dominate the drug development pipeline
| Patented Medicine Prices Review Board Canada | news releases
The latest edition of the Patented Medicine Prices Review Board (PMPRB) Meds Pipeline Monitor reports that oncology treatments made up over a third of the more than 5,500 new drugs in all phases of clinical trials in 2019.
Upward trend in market entry of high-cost drugs for rare diseases shows no sign of abating
| Patented Medicine Prices Review Board Canada | news releases
New report shows that high-cost specialty medicines account for an ever-increasing proportion of new treatments coming to market
Federal watchdog seeks public’s opinion on how to protect Canadians from excessively priced patented medicines
| Patented Medicine Prices Review Board Canada | news releases
The PMPRB is holding public consultations on its proposed new pricing Guidelines
Public drug plan expenditures in Canada rose by $2 billion over 3-year period
| Patented Medicine Prices Review Board Canada | news releases
Expenditures on drugs in public plans have increased by an average of 6.6% annually since 2014-15
Canadians benefitting from substantially lower generic drug prices
| Patented Medicine Prices Review Board Canada | news releases
Latest agreement between public payers and the Canadian generic industry closes gap with international prices
Statement by PMPRB Chairperson on changes to the Patented Medicines Regulations
| Patented Medicine Prices Review Board Canada | statements
Patented Medicine Prices Review Board (PMPRB) Chairperson Dr. Mitchell Levine made the following statement regarding Health Canada’s final amendments to the Patented Medicines Regulations, which were announced today
New PMPRB Report examines most promising medicines currently in clinical trials worldwide
| Patented Medicine Prices Review Board Canada | news releases
The Patented Medicine Prices Review Board (PMPRB), through the National Prescription Drug Utilization Information System (NPDUIS) research initiative, today published the 2018 edition of Meds Pipeline Monitor.
New Drug Landscape Dominated by High-cost Medicines
| Patented Medicine Prices Review Board Canada | news releases
The Patented Medicine Prices Review Board (PMPRB), through the National Prescription Drug Utilization Information System (NPDUIS) research initiative, today published the 2017 edition of Meds Entry Watch, an annual publication that provides the latest information on new medicines entering Canadian and international markets.
Patented Medicine Prices Review Board issues a Notice of Hearing for allegations of excessive pricing of Procysbi
| Patented Medicine Prices Review Board Canada | news releases
The Patented Medicine Prices Review Board will hold a public hearing in the matter of the price of the patented medicine cysteamine bitartrate, sold under the trade name “Procysbi” by the patentee Horizon Therapeutics Canada.